<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36420736</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1398-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Allergy</Title><ISOAbbreviation>Allergy</ISOAbbreviation></Journal><ArticleTitle>Recent developments in the immunopathology of COVID-19.</ArticleTitle><Pagination><StartPage>369</StartPage><EndPage>388</EndPage><MedlinePgn>369-388</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/all.15593</ELocationID><Abstract><AbstractText>There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 (COVID-19) patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy of the COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2&#x2009;years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huan-Ping</ForeName><Initials>HP</Initials><Identifier Source="ORCID">0000-0003-2263-6774</Identifier><AffiliationInfo><Affiliation>Department of Allergology, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuan-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan-Fen</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazici</LastName><ForeName>Duygu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azkur</LastName><ForeName>Dilek</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4396-9087</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of Kirikkale, Kirikkale, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogulur</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azkur</LastName><ForeName>Ahmet Kursat</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-5597-8917</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhao-Wei</ForeName><Initials>ZW</Initials><Identifier Source="ORCID">0000-0002-1805-4360</Identifier><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao-Xue</ForeName><Initials>XX</Initials><AffiliationInfo><Affiliation>Department of Allergology, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ai-Zhi</ForeName><Initials>AZ</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, The Second Hospital of Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jia-Qian</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guang-Hui</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdis</LastName><ForeName>M&#xfc;beccel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0554-9943</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdis</LastName><ForeName>Cezmi A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0001-8020-019X</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Ya-Dong</ForeName><Initials>YD</Initials><Identifier Source="ORCID">0000-0003-1251-7608</Identifier><AffiliationInfo><Affiliation>Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Allergy</MedlineTA><NlmUniqueID>7804028</NlmUniqueID><ISSNLinking>0105-4538</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000707" MajorTopicYN="Y">Anaphylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">allergy</Keyword><Keyword MajorTopicYN="N">angiotensin-converting enzyme 2</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>C. A. Akdis has received research grants from the Swiss National Science Foundation, European Union (EU CURE, EU Syn&#x2010;Air&#x2010;G), European Union, Novartis Research Institutes, (Basel, Switzerland), Stanford University (Redwood City, Calif), and SciBase (Stockholm, Sweden); is the Co&#x2010;Chair for EAACI Guidelines on Environmental Science in Allergic diseases and Asthma; is on the Advisory Boards of Sanofi/Regeneron, Stanford University Sean Parker Asthma Allergy Center, Novartis, GlaxoSmithKline, Bristol&#x2010;Myers Squibb (London) and SciBase; and is the Editor&#x2010;in&#x2010;Chief of Allergy. M. Akdis has received research grants from Swiss National science Foundation, Bern; research grant from the Stanford University; Leading House for the Latin American Region, Seed Money Grant. She is in the Scientific Advisory Board member of Stanford University&#x2010;Sean Parker Asthma Allergy Center, CA; Advisory Board member of LEO Foundation Skin Immunology Research Center, Copenhagen; and Scientific Co&#x2010;Chair of World allergy Congress (WAC) Istanbul, 2022. The other authors have none to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36420736</ArticleId><ArticleId IdType="pmc">PMC10108124</ArticleId><ArticleId IdType="doi">10.1111/all.15593</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS&#x2010;CoV&#x2010;2 in Wuhan, China. Allergy. 2020;75(7):1730&#x2010;1741.</Citation><ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId></ArticleIdList></Reference><Reference><Citation>Riggioni C, Comberiati P, Giovannini M, et al. A compendium answering 150 questions on COVID&#x2010;19 and SARS&#x2010;CoV&#x2010;2. Allergy. 2020;75(10):2503&#x2010;2541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323196</ArticleId><ArticleId IdType="pubmed">32535955</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2010;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D, Wang N, Corbett KS, et al. Cryo&#x2010;EM structure of the 2019&#x2010;nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260&#x2010;1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine&#x2010;Weber H, Schroeder S, et al. SARS&#x2010;CoV&#x2010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271&#x2010;280 e278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS&#x2010;CoV&#x2010;2 and COVID&#x2010;19. Nat Rev Microbiol. 2021;19(3):141&#x2010;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly JL, Simonetti B, Klein K, et al. Neuropilin&#x2010;1 is a host factor for SARS&#x2010;CoV&#x2010;2 infection. Science. 2020;370(6518):861&#x2010;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BA, Xie X, Bailey AL, et al. Loss of furin cleavage site attenuates SARS&#x2010;CoV&#x2010;2 pathogenesis. Nature. 2021;591(7849):293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175039</ArticleId><ArticleId IdType="pubmed">33494095</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS&#x2010;CoV&#x2010;2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID&#x2010;19 risk factors. Allergy. 2020;75(11):2829&#x2010;2845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300910</ArticleId><ArticleId IdType="pubmed">32496587</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Gu Y, Wheeler B, et al. Effectiveness of Covid&#x2010;19 vaccines over a 9&#x2010;month period in North Carolina. N Engl J Med. 2022;386(10):933&#x2010;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781317</ArticleId><ArticleId IdType="pubmed">35020982</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid&#x2010;19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355&#x2010;1371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451184</ArticleId><ArticleId IdType="pubmed">34496194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS&#x2010;CoV&#x2010;2 variants. N Engl J Med. 2021;384(23):2212&#x2010;2218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117968</ArticleId><ArticleId IdType="pubmed">33882219</ArticleId></ArticleIdList></Reference><Reference><Citation>Servellita V, Syed AM, Morris MK, et al. Neutralizing immunity in vaccine breakthrough infections from the SARS&#x2010;CoV&#x2010;2 Omicron and Delta variants. Cell. 2022;185(9):1539&#x2010;1548. e1535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930394</ArticleId><ArticleId IdType="pubmed">35429436</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Cui C, Hautefort C, et al. Olfactory and gustatory dysfunction as an early identifier of COVID&#x2010;19 in adults and children: an international multicenter study. Otolaryngol Head Neck Surg. 2020;163(4):714&#x2010;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298561</ArticleId><ArticleId IdType="pubmed">32539586</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemann J, Onorato GL, Jutel M, et al. Differentiation of COVID&#x2010;19 signs and symptoms from allergic rhinitis and common cold: an ARIA&#x2010;EAACI&#x2010;GA(2) LEN consensus. Allergy. 2021;76(8):2354&#x2010;2366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250633</ArticleId><ArticleId IdType="pubmed">33730365</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID&#x2010;19: a preliminary review of an emerging issue. Br J Dermatol. 2020;183(3):431&#x2010;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300648</ArticleId><ArticleId IdType="pubmed">32479680</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SW, Tam YC, Oh CC. Skin manifestations of COVID&#x2010;19: a worldwide review. JAAD Int. 2021;2:119&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754879</ArticleId><ArticleId IdType="pubmed">33479703</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranard BL, Megjhani M, Terilli K, et al. Identification of endotypes of hospitalized COVID&#x2010;19 patients. Front Med (Lausanne). 2021;8:770343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632028</ArticleId><ArticleId IdType="pubmed">34859018</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez&#x2010;Gutierrez B, Del Toro MD, Borobia AM, et al. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID&#x2010;19: a multicentre cohort study. Lancet Infect Dis. 2021;21(6):783&#x2010;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906623</ArticleId><ArticleId IdType="pubmed">33636145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27(4):601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N. Long covid: how to define it and how to manage it. BMJ. 2020;370:m3489.</Citation><ArticleIdList><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1&#x2010;year outcomes in hospital survivors with COVID&#x2010;19: a longitudinal cohort study. Lancet. 2021;398(10302):747&#x2010;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X, Zhang L, Du H, et al. SARS&#x2010;CoV&#x2010;2 infection in children. N Engl J Med. 2020;382(17):1663&#x2010;1665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121177</ArticleId><ArticleId IdType="pubmed">32187458</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334&#x2010;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou J, Thomas PG, Randolph AG. Immunology of SARS&#x2010;CoV&#x2010;2 infection in children. Nat Immunol. 2022;23(2):177&#x2010;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8981222</ArticleId><ArticleId IdType="pubmed">35105983</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle AJ, Vito O, Patel H, et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021;385(1):11&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220965</ArticleId><ArticleId IdType="pubmed">34133854</ArticleId></ArticleIdList></Reference><Reference><Citation>Son MBF, Murray N, Friedman K, et al. Multisystem inflammatory syndrome in children &#x2013; initial therapy and outcomes. N Engl J Med. 2021;385(1):23&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220972</ArticleId><ArticleId IdType="pubmed">34133855</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodino KG, Smith KP, Pettengill MA. Novel assays for molecular detection of severe acute respiratory syndrome coronavirus 2. Clin Lab Med. 2022;42(2):299&#x2010;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8904158</ArticleId><ArticleId IdType="pubmed">35636828</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekonnen D, Mengist HM, Derbie A, et al. Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: a systematic review and meta&#x2010;analysis. Rev Med Virol. 2021;31(3):e2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">33152146</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiereghin A, Zagari RM, Galli S, et al. Recent advances in the evaluation of serological assays for the diagnosis of SARS&#x2010;CoV&#x2010;2 infection and COVID&#x2010;19. Front Public Health. 2020;8:620222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7929977</ArticleId><ArticleId IdType="pubmed">33681115</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Finana M, Buchan IE. Rapid antigen testing in COVID&#x2010;19 responses. Science. 2021;372(6542):571&#x2010;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">33958462</ArticleId></ArticleIdList></Reference><Reference><Citation>Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS&#x2010;CoV&#x2010;2 infections. Nat Med. 2020;26(8):1200&#x2010;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Han MS, Choi EH, Chang SH, et al. Clinical characteristics and viral RNA detection in children with coronavirus disease 2019 in the Republic of Korea. JAMA Pediatr. 2021;175(1):73&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455883</ArticleId><ArticleId IdType="pubmed">32857112</ArticleId></ArticleIdList></Reference><Reference><Citation>Radermecker C, Detrembleur N, Guiot J, et al. Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID&#x2010;19. J Exp Med. 2020;217(12), e20201012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488867</ArticleId><ArticleId IdType="pubmed">32926097</ArticleId></ArticleIdList></Reference><Reference><Citation>Veras FP, Pontelli MC, Silva CM, et al. SARS&#x2010;CoV&#x2010;2&#x2010;triggered neutrophil extracellular traps mediate COVID&#x2010;19 pathology. J Exp Med. 2020;217(12), e20201129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488868</ArticleId><ArticleId IdType="pubmed">32926098</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for COVID&#x2010;19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2022. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767775</ArticleId><ArticleId IdType="pubmed">35044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID&#x2010;19 patients: a review. Allergy. 2021;76(2):428&#x2010;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzenschlager S, Zimmer AJ, Gottschalk C, et al. Can we predict the severe course of COVID&#x2010;19 &#x2013; a systematic review and meta&#x2010;analysis of indicators of clinical outcome? PLoS One. 2021;16(7):e0255154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8321230</ArticleId><ArticleId IdType="pubmed">34324560</ArticleId></ArticleIdList></Reference><Reference><Citation>Du R, Tsougenis ED, Ho JWK, et al. Machine learning application for the prediction of SARS&#x2010;CoV&#x2010;2 infection using blood tests and chest radiograph. Sci Rep. 2021;11(1):14250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270945</ArticleId><ArticleId IdType="pubmed">34244563</ArticleId></ArticleIdList></Reference><Reference><Citation>Styrzynski F, Zhakparov D, Schmid M, et al. Machine learning successfully detects COVID&#x2010;19 patients prior to PCR results and predicts their survival based on standard laboratory parameters. SSRN. 2022;Preprint.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9638383</ArticleId><ArticleId IdType="pubmed">36333475</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldane V, De Foo C, Abdalla SM, et al. Health systems resilience in managing the COVID&#x2010;19 pandemic: lessons from 28 countries. Nat Med. 2021;27(6):964&#x2010;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">34002090</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar LE, Molina&#x2010;Cruz A, Barillas&#x2010;Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID&#x2010;19). Proc Natl Acad Sci USA. 2020;117(30):17720&#x2010;17726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395502</ArticleId><ArticleId IdType="pubmed">32647056</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyasaka M. Is BCG vaccination causally related to reduced COVID&#x2010;19 mortality? EMBO Mol Med. 2020;12(6):e12661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267326</ArticleId><ArticleId IdType="pubmed">32379923</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos&#x2010;Bourboulis EJ, Tsilika M, Moorlag S, et al. Activate: randomized clinical trial of BCG vaccination against infection in the elderly. Cell. 2020;183(2):315&#x2010;323 e319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462457</ArticleId><ArticleId IdType="pubmed">32941801</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea MG, Giamarellos&#x2010;Bourboulis EJ, Dominguez&#x2010;Andres J, et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS&#x2010;CoV&#x2010;2 infection. Cell. 2020;181(5):969&#x2010;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196902</ArticleId><ArticleId IdType="pubmed">32437659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg L, Bygdell M, Stukat von Feilitzen G, et al. Recent MMR vaccination in health care workers and Covid&#x2010;19: a test negative case&#x2010;control study. Vaccine. 2021;39(32):4414&#x2010;4418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8216866</ArticleId><ArticleId IdType="pubmed">34187707</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Baumgartl WH, Okyay RA, et al. Analysis of measles&#x2010;mumps&#x2010;rubella (MMR) titers of recovered COVID&#x2010;19 patients. mBio. 2020;11(6):e02628&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7686805</ArticleId><ArticleId IdType="pubmed">33219096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdemir O. Measles&#x2010;mumps&#x2010;rubella vaccine and COVID&#x2010;19 relationship. mBio. 2020;11(5):e01832&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7512551</ArticleId><ArticleId IdType="pubmed">32963005</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AB, Verma A. Nasal ACE2 levels and COVID&#x2010;19 in children. JAMA. 2020;323(23):2386&#x2010;2387.</Citation><ArticleIdList><ArticleId IdType="pubmed">32432681</ArticleId></ArticleIdList></Reference><Reference><Citation>Muus C, Luecken MD, Eraslan G, et al. Single&#x2010;cell meta&#x2010;analysis of SARS&#x2010;CoV&#x2010;2 entry genes across tissues and demographics. Nat Med. 2021;27(3):546&#x2010;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9469728</ArticleId><ArticleId IdType="pubmed">33654293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura H, Francisco D, Conway M, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020;146(1):80&#x2010;88. e88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227558</ArticleId><ArticleId IdType="pubmed">32422146</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison CB, Edwards CE, Shaffer KM, et al. SARS&#x2010;CoV&#x2010;2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL&#x2010;13. Proc Natl Acad Sci USA. 2022;119(16):e2119680119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9169748</ArticleId><ArticleId IdType="pubmed">35353667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonser LR, Eckalbar WL, Rodriguez L, et al. The type 2 asthma mediator IL&#x2010;13 inhibits severe acute respiratory syndrome coronavirus 2 infection of bronchial epithelium. Am J Respir Cell Mol Biol. 2022;66(4):391&#x2010;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8990122</ArticleId><ArticleId IdType="pubmed">34982656</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker N, Radzikowska U, Wawrzyniak P, et al. Regulation of mRNA transcripts, protein isoforms, glycosylation and spatial localization of ACE2 and other SARS&#x2010;CoV&#x2010;2&#x2010;associated molecules in human airway epithelium upon viral infection and type 2 inflammation. bioRxiv. 2022; preprint.</Citation></Reference><Reference><Citation>Xu Y, Gao R, Zhu G, et al. Genetic variation of allergic disease is associated with the susceptibility to COVID&#x2010;19. J Infect. 2022;84(5):e92&#x2010;e93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8759095</ArticleId><ArticleId IdType="pubmed">35038436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, Pang W, Luo Y, et al. Impact of allergic rhinitis and asthma on COVID&#x2010;19 infection, hospitalization, and mortality. J Allergy Clin Immunol Pract. 2022;10(1):124&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556867</ArticleId><ArticleId IdType="pubmed">34728408</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin C, Hummel T, Liu Z, Mullol J. Chronic rhinosinusitis and COVID&#x2010;19. J Allergy Clin Immunol Pract. 2022;10(6):1423&#x2010;1432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926942</ArticleId><ArticleId IdType="pubmed">35307579</ArticleId></ArticleIdList></Reference><Reference><Citation>Takabayashi T, Yoshida K, Imoto Y, Schleimer RP, Fujieda S. Regulation of the expression of SARS&#x2010;CoV&#x2010;2 receptor angiotensin&#x2010;converting enzyme 2 in nasal mucosa. Am J Rhinol Allergy. 2022;36(1):115&#x2010;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11066611</ArticleId><ArticleId IdType="pubmed">34232770</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin C, Tubita V, Langdon C, et al. ACE2 downregulation in olfactory mucosa: eosinophilic rhinosinusitis as COVID&#x2010;19 protective factor? Allergy. 2021;76(9):2904&#x2010;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222895</ArticleId><ArticleId IdType="pubmed">33987850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS&#x2010;CoV&#x2010;2 receptor ACE2 is an interferon&#x2010;stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016&#x2010;1035 e1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume C, Jackson CL, Spalluto CM, et al. A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. Nat Genet. 2021;53(2):205&#x2010;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">33432184</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JR, Mahdi M, Nicolau DV Jr, et al. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID&#x2010;19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respir Med. 2022;10(6):545&#x2010;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989397</ArticleId><ArticleId IdType="pubmed">35397798</ArticleId></ArticleIdList></Reference><Reference><Citation>Donlan AN, Sutherland TE, Marie C, et al. IL&#x2010;13 is a driver of COVID&#x2010;19 severity. JCI Insight. 2021;6(15):e150107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410056</ArticleId><ArticleId IdType="pubmed">34185704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasson J, Donlan AN, Ma JZ, et al. Safety and efficacy of dupilumab for the treatment of hospitalized patients with moderate to severe coronavirus disease 2019: a phase 2a trial. Open Forum Infect Dis. 2022;9(8):ofac343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9361171</ArticleId><ArticleId IdType="pubmed">35959207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator&#x2010;free in patients with moderate or severe acute respiratory distress syndrome and COVID&#x2010;19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307&#x2010;1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid&#x2010;19. N Engl J Med. 2021;384(8):693&#x2010;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Rosin NL, Arora R, et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID&#x2010;19. Nat Med. 2022;28(1):201&#x2010;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799469</ArticleId><ArticleId IdType="pubmed">34782790</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters MC, Sajuthi S, Deford P, et al. COVID&#x2010;19&#x2010;related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328313</ArticleId><ArticleId IdType="pubmed">32348692</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne S, Li X, Yang CX, et al. Inhaled corticosteroids downregulate SARS&#x2010;CoV&#x2010;2&#x2010;related genes in COPD: results from a randomised controlled trial. Eur Respir J. 2021;58(1):2100130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015643</ArticleId><ArticleId IdType="pubmed">33795322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID&#x2010;19 (STOIC): a phase 2, open&#x2010;label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763&#x2010;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8040526</ArticleId><ArticleId IdType="pubmed">33844996</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID&#x2010;19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open&#x2010;label, adaptive platform trial. Lancet. 2021;398(10303):843&#x2010;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354567</ArticleId><ArticleId IdType="pubmed">34388395</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YC, Yang CF, Chen YF, et al. A siRNA targets and inhibits a broad range of SARS&#x2010;CoV&#x2010;2 infections including Delta variant. EMBO Mol Med. 2022;14(4):e15298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988202</ArticleId><ArticleId IdType="pubmed">35138028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhu W, Jin Q, et al. Inhalable nanocatchers for SARS&#x2010;CoV&#x2010;2 inhibition. Proc Natl Acad Sci USA. 2021;118(29):e2102957118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8307760</ArticleId><ArticleId IdType="pubmed">34292870</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, et al. Considerable escape of SARS&#x2010;CoV&#x2010;2 Omicron to antibody neutralization. Nature. 2022;602(7898):671&#x2010;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim SSA, Karim QA. Omicron SARS&#x2010;CoV&#x2010;2 variant: a new chapter in the COVID&#x2010;19 pandemic. Lancet. 2021;398(10317):2126&#x2010;2128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8640673</ArticleId><ArticleId IdType="pubmed">34871545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, et al. Covid&#x2010;19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474&#x2010;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kousathanas A, Pairo&#x2010;Castineira E, Rawlik K, et al. Whole genome sequencing reveals host factors underlying critical Covid&#x2010;19. Nature. 2022:97&#x2010;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259496</ArticleId><ArticleId IdType="pubmed">35255492</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk factors for COVID&#x2010;19&#x2010;associated hospitalisations and death: systematic review and meta&#x2010;analysis. BMJ Nutr Prev Health. 2022;5(1):10&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8783972</ArticleId><ArticleId IdType="pubmed">35814718</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonafine CP, Paiatto BNM, Leal FB, et al. High prevalence of SARS&#x2010;CoV&#x2010;2 infection among symptomatic healthcare workers in a large university tertiary hospital in Sao Paulo, Brazil. BMC Infect Dis. 2020;20(1):917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709093</ArticleId><ArticleId IdType="pubmed">33267836</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampoor S, Hesamizadeh K, Maleki F, et al. A possible pathogenic correlation between neutrophil elastase (NE) enzyme and inflammation in the pathogenesis of coronavirus disease 2019 (COVID&#x2010;19). Int Immunopharmacol. 2021;100:108137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437823</ArticleId><ArticleId IdType="pubmed">34536744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard BA, Colovos C, Lawson MA, et al. Increased histone&#x2010;DNA complexes and endothelial&#x2010;dependent thrombin generation in severe COVID&#x2010;19. Vascul Pharmacol. 2022;142:106950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8641427</ArticleId><ArticleId IdType="pubmed">34871770</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Wimmers F, Mok CKP, et al. Systems biological assessment of immunity to mild versus severe COVID&#x2010;19 infection in humans. Science. 2020;369(6508):1210&#x2010;1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Effort CHG, Cobat A, Casanova JL. Human genetic and immunological determinants of critical COVID&#x2010;19 pneumonia. Nature. 2022;603(7902):587&#x2010;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957595</ArticleId><ArticleId IdType="pubmed">35090163</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID&#x2010;19 infection risk and mortality: a systematic review and meta&#x2010;analysis. Blood Rev. 2021;48:100785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834371</ArticleId><ArticleId IdType="pubmed">33309392</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID&#x2010;19&#x2010;related death using OpenSAFELY. Nature. 2020;584(7821):430&#x2010;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodby B, Arnold MM, Valacchi G. SARS&#x2010;CoV&#x2010;2 infection, COVID&#x2010;19 pathogenesis, and exposure to air pollution: what is the connection? Ann N Y Acad Sci. 2021;1486(1):15&#x2010;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675684</ArticleId><ArticleId IdType="pubmed">33022781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorito S, Soligo M, Gao Y, Ogulur I, Akdis CA, Bonini S. Is epithelial barrier hypothesis the key to understanding the higher incidence and excess mortality during COVID&#x2010;19 pandemic? The case of Northern Italy. Allergy. 2022;77(5):1408&#x2010;1417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9304271</ArticleId><ArticleId IdType="pubmed">35102595</ArticleId></ArticleIdList></Reference><Reference><Citation>Invernizzi R, Lloyd CM, Molyneaux PL. Respiratory microbiome and epithelial interactions shape immunity in the lungs. Immunology. 2020;160(2):171&#x2010;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218407</ArticleId><ArticleId IdType="pubmed">32196653</ArticleId></ArticleIdList></Reference><Reference><Citation>Annesi&#x2010;Maesano I, Maesano CN, D'Amato M, D'Amato G. Pros and cons for the role of air pollution on COVID&#x2010;19 development. Allergy. 2021;76(8):2647&#x2010;2649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251006</ArticleId><ArticleId IdType="pubmed">33733491</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghapour M, Ubags ND, Bruder D, et al. Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD. Eur Respir Rev. 2022;31(163):210112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128841</ArticleId><ArticleId IdType="pubmed">35321933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Chen H, Chan YL, Oliver BG. Is there an association between the level of ambient air pollution and COVID&#x2010;19? Am J Physiol Lung Cell Mol Physiol. 2020;319(3):L416&#x2010;L421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7839633</ArticleId><ArticleId IdType="pubmed">32697597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer MS, van Donkelaar A, Martin RV, et al. Effects of COVID&#x2010;19 lockdowns on fine particulate matter concentrations. Sci Adv. 2021;7(26):eabg7670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221629</ArticleId><ArticleId IdType="pubmed">34162552</ArticleId></ArticleIdList></Reference><Reference><Citation>Damialis A, Gilles S, Sofiev M, et al. Higher airborne pollen concentrations correlated with increased SARS&#x2010;CoV&#x2010;2 infection rates, as evidenced from 31 countries across the globe. Proc Natl Acad Sci USA. 2021;118(12):e2019034118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999946</ArticleId><ArticleId IdType="pubmed">33798095</ArticleId></ArticleIdList></Reference><Reference><Citation>Travaglio M, Yu Y, Popovic R, Selley L, Leal NS, Martins LM. Links between air pollution and COVID&#x2010;19 in England. Environ Pollut. 2021;268(Pt A):115859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571423</ArticleId><ArticleId IdType="pubmed">33120349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozack A, Pierre S, DeFelice N, et al. Long&#x2010;term air pollution exposure and COVID&#x2010;19 mortality: a patient&#x2010;level analysis from New York City. Am J Respir Crit Care Med. 2022;205(6):651&#x2010;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">34881681</ArticleId></ArticleIdList></Reference><Reference><Citation>Dales R, Blanco&#x2010;Vidal C, Romero&#x2010;Meza R, Schoen S, Lukina A, Cakmak S. The association between air pollution and COVID&#x2010;19 related mortality in Santiago, Chile: a daily time series analysis. Environ Res. 2021;198:111284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8547777</ArticleId><ArticleId IdType="pubmed">33971125</ArticleId></ArticleIdList></Reference><Reference><Citation>Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of SARS&#x2010;CoV&#x2010;2. Science. 2022;375(6585):1116&#x2010;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9009722</ArticleId><ArticleId IdType="pubmed">35271324</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS&#x2010;CoV&#x2010;2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182(5):1295&#x2010;1310. e1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS&#x2010;CoV&#x2010;2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS&#x2010;CoV&#x2010;2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266&#x2010;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">33767447</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar MS, Marwal R, Vs R, et al. Genomic characterization and epidemiology of an emerging SARS&#x2010;CoV&#x2010;2 variant in Delhi, India. Science. 2021;374(6570):995&#x2010;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612010</ArticleId><ArticleId IdType="pubmed">34648303</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P, Kemp SA, Dhar MS, et al. SARS&#x2010;CoV&#x2010;2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS&#x2010;CoV&#x2010;2 Omicron variant in southern Africa. Nature. 2022;603(7902):679&#x2010;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Balloux F, Tan C, Swadling L, et al. The past, current and future epidemiological dynamic of SARS&#x2010;CoV&#x2010;2. Oxf Open Immunol. 2022;3(1):iqac003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278178</ArticleId><ArticleId IdType="pubmed">35872966</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS&#x2010;CoV&#x2010;2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303&#x2010;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Abdullahi A, Ferreira I, et al. Altered TMPRSS2 usage by SARS&#x2010;CoV&#x2010;2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706&#x2010;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui KPY, Ho JCW, Cheung MC, et al. SARS&#x2010;CoV&#x2010;2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603(7902):715&#x2010;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H, Moir M, Everatt J, et al. Emergence of SARS&#x2010;CoV&#x2010;2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28(9):1785&#x2010;1790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9499863</ArticleId><ArticleId IdType="pubmed">35760080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chen R, Hu F, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS&#x2010;CoV&#x2010;2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021;40:101129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8435265</ArticleId><ArticleId IdType="pubmed">34541481</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. What Omicron's BA.4 and BA.5 variants mean for the pandemic. Nature. 2022;606(7916):848&#x2010;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">35750920</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan T, Boes S, McCullough M, et al. First detection of SARS&#x2010;CoV&#x2010;2 Omicron BA.4 variant in Western Pennsylvania, United States. J Med Virol. 2022;94(9):4053&#x2010;4055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348449</ArticleId><ArticleId IdType="pubmed">35534788</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian F, Yu Y, Song W, et al. Further humoral immunity evasion of emerging SARS&#x2010;CoV&#x2010;2 BA.4 and BA.5 subvariants. Lancet Infect Dis. 2022;22(11):1535&#x2010;1537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9514837</ArticleId><ArticleId IdType="pubmed">36179744</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593&#x2010;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A, Nutalai R, Dijokaite&#x2010;Guraliuc A, et al. Antibody escape of SARS&#x2010;CoV&#x2010;2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422&#x2010;2433 e2413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS&#x2010;CoV&#x2010;2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387(1):86&#x2010;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135&#x2010;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553670</ArticleId><ArticleId IdType="pubmed">23297263</ArticleId></ArticleIdList></Reference><Reference><Citation>Neugebauer F, Bergs S, Liebert UG, Honemann M. Human rhinoviruses in pediatric patients in a Tertiary Care Hospital in Germany: molecular epidemiology and clinical significance. Viruses. 2022;14(8):1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9415293</ArticleId><ArticleId IdType="pubmed">36016451</ArticleId></ArticleIdList></Reference><Reference><Citation>Peteranderl C, Herold S, Schmoldt C. Human influenza virus infections. Semin Respir Crit Care Med. 2016;37(4):487&#x2010;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174870</ArticleId><ArticleId IdType="pubmed">27486731</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018;16(1):47&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">29081496</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabara SM, Serdan TDA, Gorjao R, et al. SARS&#x2010;COV&#x2010;2 variants: differences and potential of immune evasion. Front Cell Infect Microbiol. 2021;11:781429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8805732</ArticleId><ArticleId IdType="pubmed">35118007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, Yin H, Yin JY. B.1.617.2 (Delta) variant of SARS&#x2010;CoV&#x2010;2: features, transmission and potential strategies. Int J Biol Sci. 2022;18(5):1844&#x2010;1851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935235</ArticleId><ArticleId IdType="pubmed">35342345</ArticleId></ArticleIdList></Reference><Reference><Citation>Le TTB, Vasanthakumaran T, Thi Hien HN, et al. SARS&#x2010;CoV&#x2010;2 Omicron and its current known unknowns: a narrative review. Rev Med Virol. 2022;e2398. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538895</ArticleId><ArticleId IdType="pubmed">36150052</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Saied AA, Emran TB, Choudhary OP. Emergence of Omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures. New Microbes New Infect. 2022;48:100997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9293046</ArticleId><ArticleId IdType="pubmed">35873063</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallei TE, Alhumaid S, AlMusa Z, et al. Update on the Omicron sub&#x2010;variants BA.4 and BA.5. Rev Med Virol. 2022;e2391. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539252</ArticleId><ArticleId IdType="pubmed">36017597</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris CP, Eldesouki RE, Sachithanandham J, et al. Omicron subvariants: clinical, laboratory, and cell culture characterization. medRxiv. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10069846</ArticleId><ArticleId IdType="pubmed">36366857</ArticleId></ArticleIdList></Reference><Reference><Citation>Basnet S, Palmenberg AC, Gern JE. Rhinoviruses and their receptors. Chest. 2019;155(5):1018&#x2010;1025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533451</ArticleId><ArticleId IdType="pubmed">30659817</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie L, Roosendahl P, Ng WC, Brooks AG, Reading PC, Londrigan SL. Endocytic function is critical for influenza A virus infection via DC&#x2010;SIGN and L&#x2010;SIGN. Sci Rep. 2016;6:19428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725901</ArticleId><ArticleId IdType="pubmed">26763587</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y, Nagao Y, Kato H, et al. Human influenza A virus hemagglutinin distinguishes sialyloligosaccharides in membrane&#x2010;associated gangliosides as its receptor which mediates the adsorption and fusion processes of virus infection. Specificity for oligosaccharides and sialic acids and the sequence to which sialic acid is attached. J Biol Chem. 1986;261(36):17057&#x2010;17061.</Citation><ArticleIdList><ArticleId IdType="pubmed">3782153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291&#x2010;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4327893</ArticleId><ArticleId IdType="pubmed">19393959</ArticleId></ArticleIdList></Reference><Reference><Citation>Goller KV, Moritz J, Ziemann J, et al. Differences in clinical presentations of Omicron infections with the lineages BA.2 and BA.5 in Mecklenburg&#x2010;Western Pomerania, Germany, between April and July 2022. Viruses. 2022;14(9):2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9506148</ArticleId><ArticleId IdType="pubmed">36146837</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YD, Agache I, Akdis M, et al. The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID&#x2010;19. Int Immunol. 2022;34(4):177&#x2010;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689956</ArticleId><ArticleId IdType="pubmed">34788827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom CI, Cullinan P, Wedzicha JA. Asthma phenotypes and COVID&#x2010;19 risk: a population&#x2010;based observational study. Am J Respir Crit Care Med. 2022;205(1):36&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865578</ArticleId><ArticleId IdType="pubmed">34669568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zein JG, Strauss R, Attaway AH, et al. Eosinophilia is associated with improved COVID&#x2010;19 outcomes in inhaled corticosteroid&#x2010;treated patients. J Allergy Clin Immunol Pract. 2022;10(3):742&#x2010;750 e714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757367</ArticleId><ArticleId IdType="pubmed">35033701</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner JO, Warner JA, Munblit D. Hypotheses to explain the associations between asthma and the consequences of COVID&#x2010;19 infection. Clin Exp Allergy. 2022;52(1):7&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34978737</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert LE, He Z, Collins W, et al. Asthma phenotypes, associated comorbidities, and long&#x2010;term symptoms in COVID&#x2010;19. Allergy. 2022;77(1):173&#x2010;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222896</ArticleId><ArticleId IdType="pubmed">34080210</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway FM, Bloom CI, Shah PL. Susceptibility of patients with airways disease to SARS&#x2010;CoV&#x2010;2 infection. Am J Respir Crit Care Med. 2022;206(6):696&#x2010;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9799128</ArticleId><ArticleId IdType="pubmed">35549839</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr TF, Kraft M. Asthma and atopy in COVID&#x2010;19: 2021 updates. J Allergy Clin Immunol. 2022;149(2):562&#x2010;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8687714</ArticleId><ArticleId IdType="pubmed">34942236</ArticleId></ArticleIdList></Reference><Reference><Citation>Adir Y, Saliba W, Beurnier A, Humbert M. Asthma and COVID&#x2010;19: an update. Eur Respir Rev. 2021;30(162):210152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674937</ArticleId><ArticleId IdType="pubmed">34911694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaietto K, Freeman MC, DiCicco LA, et al. Asthma as a risk factor for hospitalization in children with COVID&#x2010;19: a nested case&#x2010;control study. Pediatr Allergy Immunol. 2022;33(1):e13696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646549</ArticleId><ArticleId IdType="pubmed">34775650</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Xu J, Hou H, Yang H, Wang Y. Significant association of pre&#x2010;existing asthma with an increased risk for ICU admission among COVID&#x2010;19 patients: evidence based on a meta&#x2010;analysis. J Infect. 2022;84(3):418&#x2010;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9428744</ArticleId><ArticleId IdType="pubmed">34856229</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo JL, Soriano JB. Biologics may have a beneficial effect in asthma patients with COVID&#x2010;19. Eur Respir J. 2021;58(2):2101076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287737</ArticleId><ArticleId IdType="pubmed">34244322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141(5):1735&#x2010;1743 e1739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013066</ArticleId><ArticleId IdType="pubmed">28870461</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS&#x2010;CoV&#x2010;2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203&#x2010;206 e203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175851</ArticleId><ArticleId IdType="pubmed">32333915</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmon PA, Jackson DJ, Denlinger LC. COVID&#x2010;19 infections and asthma. J Allergy Clin Immunol Pract. 2022;10(3):658&#x2010;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613003</ArticleId><ArticleId IdType="pubmed">34838708</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzikowska U, Eljaszewicz A, Tan G, et al. Rhinovirus&#x2010;induced epithelial RIG&#x2010;I inflammasome activation suppresses antiviral immunity and promotes inflammatory responses in virus&#x2010;induced asthma exacerbations and COVID&#x2010;19. MedRxiv. 2021;Preprint.</Citation></Reference><Reference><Citation>Skevaki C, Karsonova A, Karaulov A, et al. SARS&#x2010;CoV&#x2010;2 infection and COVID&#x2010;19 in asthmatics: a complex relationship. Nat Rev Immunol. 2021;21(4):202&#x2010;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901163</ArticleId><ArticleId IdType="pubmed">33623123</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D, Savale L, Noel N, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Eur Respir Rev. 2022;31(163):210185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924706</ArticleId><ArticleId IdType="pubmed">35264409</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nat Immunol. 2022;23(2):210&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in long&#x2010;COVID. Int J Infect Dis. 2021;112:217&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassmeyer M, Alpan O, Corley MJ, et al. Caspases and therapeutic potential of caspase inhibitors in moderate&#x2010;severe SARS&#x2010;CoV&#x2010;2 infection and long COVID. Allergy. 2022;77(1):118&#x2010;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222863</ArticleId><ArticleId IdType="pubmed">33993490</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID&#x2010;19 and autoimmunity. J Clin Invest. 2021;131(24):e154886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon IS, Li C, Son YM, et al. Immune signatures underlying post&#x2010;acute COVID&#x2010;19 lung sequelae. Sci Immunol. 2021;6(65):eabk1741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long&#x2010;haul COVID. Nat Immunol. 2022;23(2):194&#x2010;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID&#x2010;19. Science. 2022;375(6585):1122&#x2010;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumi T, Harada K. Immune response to SARS&#x2010;CoV&#x2010;2 in severe disease and long COVID&#x2010;19. iScience. 2022;25(8):104723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9251893</ArticleId><ArticleId IdType="pubmed">35813874</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post&#x2010;COVID&#x2010;19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737&#x2010;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr. 2021;15(3):869&#x2010;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LD, Ingram J, Sculthorpe NF. More than 100 persistent symptoms of SARS&#x2010;CoV&#x2010;2 (long COVID): a scoping review. Front Med (Lausanne). 2021;8:750378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8591053</ArticleId><ArticleId IdType="pubmed">34790680</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long&#x2010;term complications of COVID&#x2010;19. Am J Physiol Cell Physiol. 2022;322(1):C1&#x2010;C11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8721906</ArticleId><ArticleId IdType="pubmed">34817268</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Bluemke DA, Luscher TF, Neubauer S. Long COVID: post&#x2010;acute sequelae of COVID&#x2010;19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157&#x2010;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayaaslan B, Eser F, Kalem AK, et al. Post&#x2010;COVID syndrome: a single&#x2010;center questionnaire study on 1007 participants recovered from COVID&#x2010;19. J Med Virol. 2021;93(12):6566&#x2010;6574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426910</ArticleId><ArticleId IdType="pubmed">34255355</ArticleId></ArticleIdList></Reference><Reference><Citation>Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS&#x2010;CoV&#x2010;2 and mechanisms of immunopathological changes in COVID&#x2010;19. Allergy. 2020;75(7):1564&#x2010;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272948</ArticleId><ArticleId IdType="pubmed">32396996</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID&#x2010;19: mechanisms, clinical outcome, diagnostics, and perspectives &#x2013; a report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020;75(10):2445&#x2010;2476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361752</ArticleId><ArticleId IdType="pubmed">32584441</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco&#x2010;Melo D, Nilsson&#x2010;Payant BE, Liu WC, et al. Imbalanced host response to SARS&#x2010;CoV&#x2010;2 drives development of COVID&#x2010;19. Cell. 2020;181(5):1036&#x2010;1045 e1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggi E, Azzarone BG, Canonica GW, Moretta L. What we know and still ignore on COVID&#x2010;19 immune pathogenesis and a proposal based on the experience of allergic disorders. Allergy. 2022;77(4):1114&#x2010;1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652765</ArticleId><ArticleId IdType="pubmed">34582050</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S, Rezaei N. Role of Toll&#x2010;like receptors in the pathogenesis of COVID&#x2010;19. J Med Virol. 2021;93(5):2735&#x2010;2739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014260</ArticleId><ArticleId IdType="pubmed">33506952</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Sato S, Sotoyama Y, et al. RIG&#x2010;I triggers a signaling&#x2010;abortive anti&#x2010;SARS&#x2010;CoV&#x2010;2 defense in human lung cells. Nat Immunol. 2021;22(7):820&#x2010;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">33976430</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorne LG, Reuschl AK, Zuliani&#x2010;Alvarez L, et al. SARS&#x2010;CoV&#x2010;2 sensing by RIG&#x2010;I and MDA5 links epithelial infection to macrophage inflammation. EMBO J. 2021;40(15):e107826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209947</ArticleId><ArticleId IdType="pubmed">34101213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Riva L, Pu Y, et al. MDA5 governs the innate immune response to SARS&#x2010;CoV&#x2010;2 in lung epithelial cells. Cell Rep. 2021;34(2):108628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832566</ArticleId><ArticleId IdType="pubmed">33440148</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues TS, de Sa KSG, Ishimoto AY, et al. Inflammasomes are activated in response to SARS&#x2010;CoV&#x2010;2 infection and are associated with COVID&#x2010;19 severity in patients. J Exp Med. 2021;218(3):e20201707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen&#x2010;specific adaptive immunity to SARS&#x2010;CoV&#x2010;2 in acute COVID&#x2010;19 and associations with age and disease severity. Cell. 2020;183(4):996&#x2010;1012. e1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Galati D, Zanotta S, Capitelli L, Bocchino M. A bird's eye view on the role of dendritic cells in SARS&#x2010;CoV&#x2010;2 infection: perspectives for immune&#x2010;based vaccines. Allergy. 2022;77(1):100&#x2010;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441836</ArticleId><ArticleId IdType="pubmed">34245591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID&#x2010;19 patients. Science. 2020;369(6504):718&#x2010;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. Auto&#x2010;antibodies against type I IFNs in patients with life&#x2010;threatening COVID&#x2010;19. Science. 2020;370(65):eabd4585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID&#x2010;19. Nature. 2021;595(7866):283&#x2010;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Beltran WF, Lam EC, Astudillo MG, et al. COVID&#x2010;19&#x2010;neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476&#x2010;488. e411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungar B, Lavin L, Golant AK, et al. The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2&#x2010;coronavirus disease 2019 antibody responses in patients with atopic dermatitis. Ann Allergy Asthma Immunol. 2022;128(6):734&#x2010;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8956356</ArticleId><ArticleId IdType="pubmed">35346880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sananez I, Raiden SC, Algieri SC, et al. A poor and delayed anti&#x2010;SARS&#x2010;CoV2 IgG response is associated to severe COVID&#x2010;19 in children. EBioMedicine. 2021;72:103615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8502533</ArticleId><ArticleId IdType="pubmed">34649078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardicli O, Carli T, Satitsuksanoa P, et al. Exposure to avian coronavirus vaccines is associated with increased levels of SARS&#x2010;CoV&#x2010;2&#x2010;cross&#x2010;reactive antibodies. Allergy. 2022;7(12):3648&#x2010;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9467642</ArticleId><ArticleId IdType="pubmed">35869837</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda LB, Netland J, Shehata L, et al. Functional SARS&#x2010;CoV&#x2010;2&#x2010;specific immune memory persists after mild COVID&#x2010;19. Cell. 2021;184(1):169&#x2010;183. e117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682481</ArticleId><ArticleId IdType="pubmed">33296701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A, Chappert P, Barba&#x2010;Spaeth G, et al. Maturation and persistence of the anti&#x2010;SARS&#x2010;CoV&#x2010;2 memory B cell response. Cell. 2021;184(5):1201&#x2010;1213. e1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994111</ArticleId><ArticleId IdType="pubmed">33571429</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattini S, Malizia V, Travaglini A, et al. Telemedicine for allergic patients during COVID&#x2010;19. Pediatr Allergy Immunol. 2020;31(Suppl 26):102&#x2010;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753788</ArticleId><ArticleId IdType="pubmed">33236424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet J, Akdis CA, Jutel M, et al. Intranasal corticosteroids in allergic rhinitis in COVID&#x2010;19 infected patients: an ARIA&#x2010;EAACI statement. Allergy. 2020;75(10):2440&#x2010;2444.</Citation><ArticleIdList><ArticleId IdType="pubmed">32233040</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss R, Jawhari N, Attaway AH, et al. Intranasal corticosteroids are associated with better outcomes in coronavirus disease 2019. J Allergy Clin Immunol Pract. 2021;9(11):3934&#x2010;3940 e3939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381621</ArticleId><ArticleId IdType="pubmed">34438103</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster KE, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the prevention of persistent post&#x2010;COVID&#x2010;19 olfactory dysfunction. Cochrane Database Syst Rev. 2021;7(7):CD013877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406518</ArticleId><ArticleId IdType="pubmed">34291812</ArticleId></ArticleIdList></Reference><Reference><Citation>Morisada MV, Hwang J, Gill AS, Wilson MD, Strong EB, Steele TO. Telemedicine, patient satisfaction, and chronic rhinosinusitis care in the era of COVID&#x2010;19. Am J Rhinol Allergy. 2021;35(4):494&#x2010;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">33115249</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaney T, Salman D, Samee T, Mak V. Assessment and management of adults with asthma during the covid&#x2010;19 pandemic. BMJ. 2020;369:m2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">32513811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ari A. Use of aerosolised medications at home for COVID&#x2010;19. Lancet Respir Med. 2020;8(8):754&#x2010;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308028</ArticleId><ArticleId IdType="pubmed">32585138</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimek L, Pfaar O, Worm M, et al. Allergen immunotherapy in the current COVID&#x2010;19 pandemic: a position paper of AeDA, ARIA, EAACI, DGAKI and GPA: position paper of the German ARIA Group (A) in cooperation with the Austrian ARIA Group (B), the Swiss ARIA Group (C), German Society for Applied Allergology (AEDA) (D), German Society for Allergology and Clinical Immunology (DGAKI) (E), Society for Pediatric Allergology (GPA) (F) in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO&#x2010;KHC (G) and the European Academy of Allergy and Clinical Immunology (EAACI) (H). Allergol Select. 2020;4:44&#x2010;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304289</ArticleId><ArticleId IdType="pubmed">32568272</ArticleId></ArticleIdList></Reference><Reference><Citation>Compalati E, Erlewyn&#x2010;Lajeunesse M, Runa Ali F, et al. Allergen immunotherapy in the era of SARS&#x2010;CoV&#x2010;2. J Investig Allergol Clin Immunol. 2020;30(6):459&#x2010;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">32394897</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez&#x2010;Lopez A, Cuenca&#x2010;Barrales C, Montero&#x2010;Vilchez T, Molina&#x2010;Leyva A, Arias&#x2010;Santiago S. Review of adverse cutaneous reactions of pharmacologic interventions for COVID&#x2010;19: a guide for the dermatologist. J Am Acad Dermatol. 2020;83(6):1738&#x2010;1748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7413159</ArticleId><ArticleId IdType="pubmed">32777318</ArticleId></ArticleIdList></Reference><Reference><Citation>Dordal Culla MT, Herrera&#x2010;Lasso Regas V, Marti&#x2010;Garrido J, Rodriguez Cumplido D, Vazquez&#x2010;Revuelta P, Lleonart BR. Treating COVID&#x2010;19: review of drug hypersensitivity reactions. J Investig Allergol Clin Immunol. 2020;30(6):385&#x2010;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">32700681</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly Thomas ZR, Leuppi&#x2010;Taegtmeyer A, Jamiolkowski D, et al. Emerging treatments in COVID&#x2010;19: adverse drug reactions including drug hypersensitivities. J Allergy Clin Immunol. 2020;146(4):786&#x2010;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833501</ArticleId><ArticleId IdType="pubmed">32710973</ArticleId></ArticleIdList></Reference><Reference><Citation>Virant FS, Randolph C, Nanda A, et al. Pulmonary procedures during the COVD&#x2010;19 pandemic: a workgroup report of the American Academy of Allergy, Asthma, and Immunology (AAAAI) asthma diagnosis and treatment (ADT) interest section. J Allergy Clin Immunol Pract. 2022;10(6):1474&#x2010;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9009724</ArticleId><ArticleId IdType="pubmed">35431153</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan A, Laveneziana P, Bayat S, et al. International consensus on lung function testing during the COVID&#x2010;19 pandemic and beyond. ERJ Open Res. 2022;8(1):00602&#x2010;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8607240</ArticleId><ArticleId IdType="pubmed">35261912</ArticleId></ArticleIdList></Reference><Reference><Citation>Oreskovic NM, Kinane TB, Aryee E, Kuhlthau KA, Perrin JM. The unexpected risks of COVID&#x2010;19 on asthma control in children. J Allergy Clin Immunol Pract. 2020;8(8):2489&#x2010;2491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7263244</ArticleId><ArticleId IdType="pubmed">32497662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez N, Sanclemente G, Tamayo L, Lopez A, Seidel A, Colombian Atopic Dermatitis Research Group M . Atopic dermatitis in the COVID&#x2010;19 era: results from a web&#x2010;based survey. World Allergy Organ J. 2021;14(8):100571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8384050</ArticleId><ArticleId IdType="pubmed">34457107</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#x2010;Qushayri AE, Mahmoud MA, Salman S, Sarsik S, Nardone B. Dupilumab therapy in atopic dermatitis is safe during COVID&#x2010;19 infection era: a systematic review and meta&#x2010;analysis of 1611 patients. Dermatol Ther. 2022;35(6):e15476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111465</ArticleId><ArticleId IdType="pubmed">35357060</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaar O, Hamelmann E, Klimek L, et al. Allergen immunotherapy during the COVID&#x2010;19 pandemic&#x2010;A survey of the German Society for Allergy and Clinical Immunology. Clin Transl Allergy. 2022;12(3):e12134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967257</ArticleId><ArticleId IdType="pubmed">35344300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez Del Rio P, Caimmi D, Rico P, et al. Real&#x2010;life report of allergen immunotherapy management during the COVID&#x2010;19 outbreak in France and Spain. Clin Exp Allergy. 2022;52(1):167&#x2010;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653094</ArticleId><ArticleId IdType="pubmed">34747540</ArticleId></ArticleIdList></Reference><Reference><Citation>Akca HM, Tuncer KK. Evaluation of urticaria patients before and during the period of the COVID&#x2010;19 pandemic: a retrospective study. Dermatol Ther. 2021;34(2):e14800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995003</ArticleId><ArticleId IdType="pubmed">33486861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulu H, Atasoy M, Ozyurt K, et al. The COVID&#x2010;19 pandemic affects male patients with chronic spontaneous urticaria more than female patients. Front Immunol. 2021;12:722406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8600565</ArticleId><ArticleId IdType="pubmed">34804011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitamura Y, Schulz D, Oro S, et al. Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID&#x2010;19 patients. Allergy. 2022;77(2):595&#x2010;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441838</ArticleId><ArticleId IdType="pubmed">34157151</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyton RJ, Altmann DM. Risk of SARS&#x2010;CoV&#x2010;2 reinfection after natural infection. Lancet. 2021;397(10280):1161&#x2010;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7969128</ArticleId><ArticleId IdType="pubmed">33743219</ArticleId></ArticleIdList></Reference><Reference><Citation>Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. 2021;27(4):591&#x2010;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">33846611</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID&#x2010;19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626&#x2010;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Krammer F, Regev&#x2010;Yochay G, Lustig Y, Balicer RD. SARS&#x2010;CoV&#x2010;2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22(1):57&#x2010;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8649989</ArticleId><ArticleId IdType="pubmed">34876702</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinger P, Niespodziana K, Stiasny K, et al. Neutralization of SARS&#x2010;CoV&#x2010;2 requires antibodies against conformational receptor&#x2010;binding domain epitopes. Allergy. 2022;77(1):230&#x2010;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653362</ArticleId><ArticleId IdType="pubmed">34453317</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ, van der Merwe PA. Effects of common mutations in the SARS&#x2010;CoV&#x2010;2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife. 2021;10:e70658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480977</ArticleId><ArticleId IdType="pubmed">34435953</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel M, Augusto G, Chang X, et al. Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor&#x2010;binding domain mutations: receptor affinity versus neutralization of receptor interaction. Allergy. 2022;77(1):143&#x2010;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441680</ArticleId><ArticleId IdType="pubmed">34240429</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS&#x2010;CoV&#x2010;2 spike protein variants. Elife. 2020;9:e61312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654&#x2010;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866126</ArticleId><ArticleId IdType="pubmed">35016196</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreno JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS&#x2010;CoV&#x2010;2 Omicron. Nature. 2022;602(7898):682&#x2010;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremsner PG, Ahuad Guerrero RA, Arana&#x2010;Arri E, et al. Efficacy and safety of the CVnCoV SARS&#x2010;CoV&#x2010;2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer&#x2010;blinded, placebo&#x2010;controlled, phase 2b/3 trial. Lancet Infect Dis. 2022;22(3):329&#x2010;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8610426</ArticleId><ArticleId IdType="pubmed">34826381</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebre MS, Rauch S, Roth N, et al. Optimization of non&#x2010;coding regions for a non&#x2010;modified mRNA COVID&#x2010;19 vaccine. Nature. 2022;601(7893):410&#x2010;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8770133</ArticleId><ArticleId IdType="pubmed">34794169</ArticleId></ArticleIdList></Reference><Reference><Citation>Badano MN, Sabbione F, Keitelman I, et al. Humoral response to the BBIBP&#x2010;CorV vaccine over time in healthcare workers with or without exposure to SARS&#x2010;CoV&#x2010;2. Mol Immunol. 2022;143:94&#x2010;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761547</ArticleId><ArticleId IdType="pubmed">35091231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaewborisuth C, Wanitchang A, Koonpaew S, et al. Chimeric virus&#x2010;like particle&#x2010;based COVID&#x2010;19 vaccine confers strong protection against SARS&#x2010;CoV&#x2010;2 viremia in K18&#x2010;hACE2 mice. Vaccines (Basel). 2022;10(5):786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9143195</ArticleId><ArticleId IdType="pubmed">35632541</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkmann A, Koopman G, Mooij P, et al. A capsid virus&#x2010;like particle&#x2010;based SARS&#x2010;CoV&#x2010;2 vaccine induces high levels of antibodies and protects rhesus macaques. Front Immunol. 2022;13:857440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9037084</ArticleId><ArticleId IdType="pubmed">35479095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinger P, Kratzer B, Tulaeva I, et al. Vaccine based on folded RBD&#x2010;PreS fusion protein with potential to induce sterilizing immunity to SARS&#x2010;CoV&#x2010;2 variants. Allergy. 2022;77(8):2431&#x2010;2445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111473</ArticleId><ArticleId IdType="pubmed">35357709</ArticleId></ArticleIdList></Reference><Reference><Citation>Alu A, Chen L, Lei H, Wei Y, Tian X, Wei X. Intranasal COVID&#x2010;19 vaccines: From bench to bed. EBioMedicine. 2022;76:103841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8785603</ArticleId><ArticleId IdType="pubmed">35085851</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez P, Astorgano D, Albericio G, et al. Intranasal administration of a single dose of MVA&#x2010;based vaccine candidates against COVID&#x2010;19 induced local and systemic immune responses and protects mice from a lethal SARS&#x2010;CoV&#x2010;2 infection. Front Immunol. 2022;13:995235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510595</ArticleId><ArticleId IdType="pubmed">36172368</ArticleId></ArticleIdList></Reference><Reference><Citation>Waltz E. China and India approve nasal COVID vaccines &#x2013; are they a game changer? Nature. 2022;609(7927):450.</Citation><ArticleIdList><ArticleId IdType="pubmed">36071228</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid&#x2010;19 vaccine. N Engl J Med. 2020;383(27):2603&#x2010;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA&#x2010;1273 SARS&#x2010;CoV&#x2010;2 vaccine. N Engl J Med. 2021;384(5):403&#x2010;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA&#x2010;1273 vaccine against SARS&#x2010;CoV&#x2010;2 in nonhuman primates. N Engl J Med. 2020;383(16):1544&#x2010;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7449230</ArticleId><ArticleId IdType="pubmed">32722908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guebre&#x2010;Xabier M, Patel N, Tian JH, et al. NVX&#x2010;CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS&#x2010;CoV&#x2010;2 challenge. Vaccine. 2020;38(50):7892&#x2010;7896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584426</ArticleId><ArticleId IdType="pubmed">33139139</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Costa Clemens SA, Madhi SA, et al. Single&#x2010;dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV&#x2010;19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881&#x2010;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894131</ArticleId><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector&#x2010;based heterologous prime&#x2010;boost COVID&#x2010;19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671&#x2010;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single&#x2010;dose Ad26.COV2.S vaccine against Covid&#x2010;19. N Engl J Med. 2021;384(23):2187&#x2010;2201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector&#x2010;based COVID&#x2010;19 vaccine encoding a prefusion&#x2010;stabilized SARS&#x2010;CoV&#x2010;2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5:91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7522255</ArticleId><ArticleId IdType="pubmed">33083026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercado NB, Zahn R, Wegmann F, et al. Single&#x2010;shot Ad26 vaccine protects against SARS&#x2010;CoV&#x2010;2 in rhesus macaques. Nature. 2020;586(7830):583&#x2010;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581548</ArticleId><ArticleId IdType="pubmed">32731257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1&#x2013;2a trial of Ad26.COV2.S Covid&#x2010;19 vaccine. N Engl J Med. 2021;384(19):1824&#x2010;1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821985</ArticleId><ArticleId IdType="pubmed">33440088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Marks F, Clemens JD. Looking beyond COVID&#x2010;19 vaccine phase 3 trials. Nat Med. 2021;27(2):205&#x2010;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">33469205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS&#x2010;CoV&#x2010;2 vaccine, BBV152: interim results from a double&#x2010;blind, randomised, multicentre, phase 2 trial, and 3&#x2010;month follow&#x2010;up of a double&#x2010;blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950&#x2010;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221739</ArticleId><ArticleId IdType="pubmed">33705727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS&#x2010;CoV&#x2010;2 vaccine in healthy adults aged 18&#x2010;59&#x2009;years: a randomised, double&#x2010;blind, placebo&#x2010;controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS&#x2010;CoV&#x2010;2 vaccine (CoronaVac) in healthy adults aged 60&#x2009;years and older: a randomised, double&#x2010;blind, placebo&#x2010;controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803&#x2010;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906628</ArticleId><ArticleId IdType="pubmed">33548194</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type&#x2010;5 vectored COVID&#x2010;19 vaccine: a dose&#x2010;escalation, open&#x2010;label, non&#x2010;randomised, first&#x2010;in&#x2010;human trial. Lancet. 2020;395(10240):1845&#x2010;1854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255193</ArticleId><ArticleId IdType="pubmed">32450106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Huang J, Zhang Z, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type&#x2010;5 vector&#x2010;based COVID&#x2010;19 vaccine (Ad5&#x2010;nCoV) in adults: preliminary report of an open&#x2010;label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21(12):1654&#x2010;1664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8313090</ArticleId><ArticleId IdType="pubmed">34324836</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX&#x2010;CoV2373 Covid&#x2010;19 vaccine. N Engl J Med. 2021;385(13):1172&#x2010;1183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech C, Albert G, Cho I, et al. Phase 1&#x2013;2 trial of a SARS&#x2010;CoV&#x2010;2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320&#x2010;2332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494251</ArticleId><ArticleId IdType="pubmed">32877576</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV&#x2010;19) Covid&#x2010;19 vaccine. N Engl J Med. 2021;385(25):2348&#x2010;2360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanov G, Bogdanov I, Kazandjieva J, Tsankov N. Cutaneous adverse effects of the available COVID&#x2010;19 vaccines. Clin Dermatol. 2021;39(3):523&#x2010;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8076732</ArticleId><ArticleId IdType="pubmed">34518015</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vrieze J. Pfizer's vaccine raises allergy concerns. Science. 2021;371(6524):10&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">33384356</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhumaid S, Al Mutair A, Al Alawi Z, et al. Anaphylactic and nonanaphylactic reactions to SARS&#x2010;CoV&#x2010;2 vaccines: a systematic review and meta&#x2010;analysis. Allergy Asthma Clin Immunol. 2021;17(1):109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8520206</ArticleId><ArticleId IdType="pubmed">34656181</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID&#x2010;19 mRNA vaccination. JAMA. 2021;326(14):1390&#x2010;1399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8511971</ArticleId><ArticleId IdType="pubmed">34477808</ArticleId></ArticleIdList></Reference><Reference><Citation>Maltezou HC, Anastassopoulou C, Hatziantoniou S, Poland GA, Tsakris A. Anaphylaxis rates associated with COVID&#x2010;19 vaccines are comparable to those of other vaccines. Vaccine. 2022;40(2):183&#x2010;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626274</ArticleId><ArticleId IdType="pubmed">34863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Haaf P, Kuster GM, Mueller C, et al. The very low risk of myocarditis and pericarditis after mRNA COVID&#x2010;19 vaccination should not discourage vaccination. Swiss Med Wkly. 2021;151:w30087.</Citation><ArticleIdList><ArticleId IdType="pubmed">34668687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau CL, Galea I. Risk&#x2010;benefit analysis of COVID&#x2010;19 vaccines &#x2013; a neurological perspective. Nat Rev Neurol. 2022;18(2):69&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8687148</ArticleId><ArticleId IdType="pubmed">34931027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellanti JA. COVID&#x2010;19 vaccines and vaccine hesitancy: role of the allergist/immunologist in promotion of vaccine acceptance. Allergy Asthma Proc. 2021;42(5):386&#x2010;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8677491</ArticleId><ArticleId IdType="pubmed">34372964</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaud A, Garvey LH, Arcolaci A, et al. Allergies and COVID&#x2010;19 vaccines: an ENDA/EAACI position paper. Allergy. 2022;77(8):2292&#x2010;2312.</Citation><ArticleIdList><ArticleId IdType="pubmed">35112371</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvey LH, Nasser S. Anaphylaxis to the first COVID&#x2010;19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2021;126(3):e106&#x2010;e108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834677</ArticleId><ArticleId IdType="pubmed">33386124</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner PJ, Ansotegui IJ, Campbell DE, et al. COVID&#x2010;19 vaccine&#x2010;associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2):100517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857113</ArticleId><ArticleId IdType="pubmed">33558825</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone CA Jr, Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533&#x2010;1540. e1538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6706272</ArticleId><ArticleId IdType="pubmed">30557713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigini P, Gobbi M, Bonati M, et al. The role and impact of polyethylene glycol on anaphylactic reactions to COVID&#x2010;19 nano&#x2010;vaccines. Nat Nanotechnol. 2021;16(11):1169&#x2010;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">34732846</ArticleId></ArticleIdList></Reference><Reference><Citation>Troelnikov A, Perkins G, Yuson C, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J Allergy Clin Immunol. 2021;148(1):91&#x2010;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">33991580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou ZH, Stone CA Jr, Jakubovic B, et al. Anti&#x2010;PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2021;9(4):1731&#x2010;1733 e1733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8090930</ArticleId><ArticleId IdType="pubmed">33217616</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk VE. Anaphylaxis associated with the mRNA COVID&#x2010;19 vaccines: approach to allergy investigation. Clin Immunol. 2021;227:108748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8080508</ArticleId><ArticleId IdType="pubmed">33932618</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of currently authorized COVID&#x2010;19 vaccines. J Investig Allergol Clin Immunol. 2021;31(1):92&#x2010;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">33433387</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolowska M, Eiwegger T, Ollert M, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID&#x2010;19 vaccines. Allergy. 2021;76(6):1629&#x2010;1639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013422</ArticleId><ArticleId IdType="pubmed">33452689</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitlick MM, Sitek AN, Kinate SA, Joshi AY, Park MA. Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: early report. Ann Allergy Asthma Immunol. 2021;126(6):735&#x2010;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997158</ArticleId><ArticleId IdType="pubmed">33775902</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren CM, Snow TT, Lee AS, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID&#x2010;19 vaccines with confirmatory testing in a US regional health system. JAMA Netw Open. 2021;4(9):e2125524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449279</ArticleId><ArticleId IdType="pubmed">34533570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson AR, Robinson LB, Li L, et al. First&#x2010;dose mRNA COVID&#x2010;19 vaccine allergic reactions: limited role for excipient skin testing. J Allergy Clin Immunol Pract. 2021;9(9):3308&#x2010;3320. e3303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8217699</ArticleId><ArticleId IdType="pubmed">34166844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli&#x2010;Pamnani A, Zapata K, Gibson T, Kwittken PL. Coronavirus disease 2019 messenger RNA vaccine skin tests and serum histamine levels in allergic reactions. Ann Allergy Asthma Immunol. 2022;128(3):339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863136</ArticleId><ArticleId IdType="pubmed">35216745</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurich S, Dolle&#x2010;Bierke S, Francuzik W, et al. Anaphylaxis in elderly patients&#x2010;data from the European Anaphylaxis Registry. Front Immunol. 2019;10:750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491699</ArticleId><ArticleId IdType="pubmed">31068925</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang V, Leung ASY, Au EYL, et al. Updated consensus statements on COVID&#x2010;19 Vaccine Allergy Safety in Hong Kong. Asia Pac Allergy. 2022;12(1):e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8819424</ArticleId><ArticleId IdType="pubmed">35174059</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS&#x2010;CoV&#x2010;2 vaccines and recommended evaluation and management: a systematic review, meta&#x2010;analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9(10):3546&#x2010;3567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248554</ArticleId><ArticleId IdType="pubmed">34153517</ArticleId></ArticleIdList></Reference><Reference><Citation>Albery GF, Becker DJ, Brierley L, et al. The science of the host&#x2010;virus network. Nat Microbiol. 2021;6(12):1483&#x2010;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">34819645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucharski AJ, Cohen C. Effective surveillance of variants. Science. 2022;375(6587):1349&#x2010;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">35324314</ArticleId></ArticleIdList></Reference><Reference><Citation>Telenti A, Arvin A, Corey L, et al. After the pandemic: perspectives on the future trajectory of COVID&#x2010;19. Nature. 2021;596(7873):495&#x2010;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">34237771</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ. COVID&#x2010;19 vaccination: the road ahead. Science. 2022;375(6585):1127&#x2010;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">35271316</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>